OBJECTIVE: To probe into the effect of teriparatide on bone mineral density（ BMD） and serum beta C-terminal telopeptide of type Ⅰ collagen（ β-CTX）

type 1 procollagen amino terminal propeptide（ P1 NP）

osteocalcin（ OCN） in elderly patients with hip fracture. METHODS: A randomized controlled trial was performed

totally 70 elderly patients with hip fracture admitted into Beijing Jishuitan Hospital during 2017-2018 were selected and divided into teriparatide group and control group via random number table

with 35 cases in each group. Interventions were conducted on the first postoperative day

the control group was treated with anti-osteoporosis drugs

while the teriparatide group was given teriparatide based on the control group. Changes of serum β-CTX

P1 NP and OCN levels of before treatment

after 14 d and 28 d of treatment

changes of BMD levels of before treatment and 6 months after treatment were observed. RESULTS: After 6-month treatment

the BMD of lumbar spine（ L

1

-L

4

） of patients in both groups were measured by quantitative CT

the results showed that the BMD of lumbar spine（ L

1

-L

4

） of teriparatide group was significantly higher than that of before treatment and after treatment in the control group

with statistically significant difference（ P

<

0. 05）. After 14 d and 28 d of treatment

the serum β-CTX level of teriparatide group was slightly lower than that of before treatment and the control groups

but the differences were not statistically significant（ P

>

0. 05）. After 14 d and 28 d of treatment

the serum P1 NP and OCN levels of teriparatide group were significantly higher than those of before treatment and the control group

with statistically significant differences（ P

<

0. 05）.CONCLUSIONS: Early application of teriparatide combined with anti-osteoporosis drugs in elderly patients with hip fracture can significantly increase serum P1 NP and OCN levels

and improve patients’ BMD.